Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

The stock's fall snapped a three-day winning streak.

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Merck & Co. Inc.-0.03% $250.86B ...